Sleep Optimization

Also known as: Delta Sleep, Hypnos

Delta sleep-inducing peptide (DSIP) is a nonapeptide — a 9-amino-acid neuropeptide with sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE, 848 Da molecular weight) — first isolated in 1977 from the cerebral venous blood of rabbits subjected to electrical stimulation of the intralaminar thalamus, a brain region involved in sleep regulation. The original Swiss investigators, Schoenenberger and Monnier at the University of Basel, named the peptide for the prominent delta-wave EEG activity they observed in recipient rabbits after intracerebroventricular injection of the purified fraction, implying a role in slow-wave (deep) sleep generation. The name, however, has proven misleading. Four decades of follow-up research have produced a pharmacological profile that is substantially more complex than "sleep peptide" — and, depending on how generously you interpret the human clinical data, somewhat less impressive than the name suggests. DSIP does not reliably produce the dramatic delta-wave surges in humans that it appeared to produce in the original rabbit EEG studies. It does, however, demonstrate real effects on sleep architecture, stress response, pain modulation, and possibly mood regulation, and it has been studied (primarily in Russian, Eastern European, and Japanese clinical literature from the 1980s-1990s) for chronic insomnia, chronic pain syndromes, alcohol and opioid withdrawal, depression, and as an adjunct to conventional sleep and anxiolytic medications. Despite 40+ years of research, DSIP has never been approved by the FDA, EMA, or any major regulatory agency for any indication. It circulates today almost exclusively through the research chemical peptide market, where it is sold as subcutaneous injection vials, nasal spray formulations, and occasionally as sublingual preparations. Users report highly variable effects — some describe profound sleep improvements from a single bedtime injection, others notice nothing at all, and a subset report vivid dreams or morning "grogginess" that can last into the next day. The compound's reputation in the biohacking community is of a "safe, non-addictive, mild-effect sleep aid" positioned as a cleaner alternative to benzodiazepines, z-drugs (zolpidem, eszopiclone), and chronic melatonin. Whether it actually deserves that reputation depends substantially on what clinical claims you are willing to accept on thin evidence. This entry covers what is genuinely established about DSIP pharmacology, what the clinical trial record actually shows (versus what marketing claims), how it is used in practice by peptide practitioners, safety considerations, and honest framing of the evidence gaps. It should be read as an educational reference, not a prescription — DSIP is not FDA-approved, is distributed through gray-market channels of variable quality, and any serious use decision should involve a qualified physician familiar with research peptides, appropriate sleep-hygiene tuning first, and realistic expectations. Cross-reference this page with Semax, Selank, and Epitalon for a complete picture of the Russian-origin "research peptide" landscape, and with BPC-157 and Tesamorelin for more thoroughly characterized peptide therapeutics.

Also known as: Epitalon

Epithalon (also spelled Epitalon, sequence Ala-Glu-Asp-Gly / AEDG) is a synthetic tetrapeptide designed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s as a short-chain analog of epithalamin, a peptide extract of bovine pineal gland. It is the most-studied "longevity peptide" in the Russian peer-reviewed literature, with over 30 years of published work on telomerase activation, telomere lengthening, melatonin restoration, and life-span extension in rodents. The core biology is three-fold: Telomerase activation in somatic cells — Khavinson and Smirnova showed that 10 ng/mL AEDG increased hTERT expression and telomerase activity in human somatic fibroblasts, extending proliferative capacity by ~42% over the Hayflick limit (Khavinson et al., 2003, Bull Exp Biol Med). Restoration of pineal melatonin secretion — In aged rats and in elderly humans, epithalon restored the nocturnal melatonin peak that declines with pineal calcification, improving circadian amplitude and sleep architecture (Anisimov et al., 2003). Direct chromatin binding (epigenetic) — NMR and X-ray studies demonstrate that AEDG binds the major groove of DNA at specific sequences, modulating transcription of interferon-γ, hTERT, and cell-cycle regulators (Fedoreyeva et al., 2011). Critical evidence-quality caveat: Unlike BPC-157 or the GLP-1 agonists, the human clinical evidence for Epithalon is almost entirely from Russian-language publications from a single research consortium (Khavinson / Anisimov / Korkushko). Western replication is minimal. The rodent data are compelling — a ~30% median life-span extension in female mice (Anisimov et al., 2003) — but translating this to human longevity remains hypothesis rather than demonstrated fact. Epithalon is used in biohacking communities for: Sleep consolidation in adults over 40 (melatonin restoration) Telomere preservation as part of a longevity stack Circadian rhythm repair after shift-work or jet lag Adjunct in age-related immunosenescence It is delivered by subcutaneous injection, typically 5-10 mg/day for 10-20 consecutive days, followed by a 3-6 month washout. This intermittent pulsing is intentional — Khavinson's protocols were always short-cycle, never continuous — and is a key safety feature in the absence of long-term continuous-dosing data.

Also known as: TP-7, Selank Spray

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 750 Da molecular weight) developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin — an immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) that is naturally cleaved from the Fc region of immunoglobulin G. The original tuftsin molecule has well-documented immunomodulatory and neurotropic effects but is rapidly degraded by peptidases in plasma, limiting its therapeutic utility. Selank adds a Pro-Gly-Pro tail to the tuftsin sequence, which confers resistance to enzymatic degradation while preserving pharmacological activity. In Russia, Selank has been approved since 2004 for the treatment of generalized anxiety disorder (GAD) and is available by prescription at pharmacies across the Russian Federation and several neighboring countries. It is marketed as a 0.15% intranasal solution under the brand name "Selank" (╨í╨╡╨╗╨░╨╜╨║) by Peptogen, a Moscow-based pharmaceutical company. In Western markets, Selank has never been submitted for FDA, EMA, or other major regulatory approval — not because of unfavorable data, but because the commercial pharmaceutical industry has no mechanism to profit from a peptide with an expired patent and no Western development sponsor. As a result, Selank circulates in the biohacking and peptide-curious community primarily as a "research chemical" through specialty peptide suppliers, where it is sold in intranasal spray or injectable formulations. The pharmacological profile of Selank is distinctive among anxiolytics. Unlike benzodiazepines, it does NOT cause sedation, cognitive dulling, tolerance, dependence, or withdrawal. Unlike SSRIs, it has rapid onset (within 30-60 minutes of intranasal administration) and effects that outlast plasma presence. Unlike buspirone, it does not require weeks of chronic dosing to manifest effects. The compound appears to work through modulation of multiple neurotransmitter systems simultaneously — GABAergic, serotonergic, dopaminergic, and endogenous opioid — producing what the Russian clinical literature describes as an "anxiolytic + nootropic" profile: the user feels calmer but also more mentally engaged, not sedated. This unusual combination has driven substantial interest in Western biohacking circles as an alternative or adjunct to conventional anxiety pharmacology. Selank has been studied in Russian clinical populations for over two decades with a consistent efficacy and safety pattern across roughly 30-50 published clinical papers. The evidence base is real but has important limitations: most trials are Russian-language, published in Russian journals, with small sample sizes (often 30-100 patients), and use Russian psychiatric rating scales rather than the validated Western instruments (GAD-7, HAM-A, Beck Anxiety Inventory) that would facilitate cross-validation. Western meta-analyses and systematic reviews are essentially nonexistent. The Russian regulatory approval is real and meaningful — Russian drug regulation, while different from FDA standards, does require efficacy and safety evidence — but it does not automatically translate to confidence in Western evidence-based medicine frameworks. For the biohacking community, Selank's appeal is the combination of (1) rapid-acting anxiolysis without sedation, (2) cognitive enhancement rather than dulling, (3) favorable safety profile across decades of Russian use, (4) non-addictive, non-dependence-producing pharmacology, and (5) intranasal delivery that is simple and needle-free. Its limitations are (1) thin Western evidence base, (2) variable quality from research chemical suppliers, (3) lack of FDA regulation or oversight, (4) modest effect magnitude in some users relative to expectations, and (5) cost relative to generic anxiety pharmacology. This entry covers the pharmacology, clinical evidence, practical use considerations, and honest framing of the evidence gaps. Cross-reference with Semax, DSIP, and Epithalon for a complete picture of the Russian research peptide landscape.

Also known as: N-acetyl-5-methoxytryptamine, 5-methoxy-N-acetyltryptamine, MLT, Circadin, Slenyto, Bio-melatonin, Melatonex, Melovine

Melatonin (chemical name N-acetyl-5-methoxytryptamine) is an endogenous neurohormone synthesized primarily by the pineal gland and, in smaller quantities, by the retina, gut, skin, bone marrow, lymphocytes, and mitochondria across most tissues. It is the body's principal circadian signaling molecule, translating environmental light/dark information into an internal chemical representation of biological night. Endogenous melatonin secretion follows a precise circadian rhythm: plasma concentrations are low during the day (typically <10 pg/mL), begin rising 1-3 hours before habitual sleep onset (the "dim light melatonin onset" or DLMO), peak between 2am and 4am at 60-70 pg/mL in healthy young adults, and decline to baseline by morning. This nightly pulse coordinates sleep initiation, thermoregulation, circadian phase, seasonal reproductive physiology in some species, antioxidant defense (particularly in mitochondria), and immune-system oscillations. Melatonin was discovered and named by Aaron Lerner at Yale in 1958 during research on pineal factors affecting amphibian skin coloration. Its role as the principal mediator of vertebrate photoperiodism was established through the 1960s-70s, its receptor targets (MT1 and MT2, both G-protein-coupled receptors) were cloned in the 1990s, and its broader pleiotropic functions beyond circadian signaling — including powerful free-radical scavenging, mitochondrial protection, oncostatic activity in hormone-sensitive tumors, immunomodulation, and metabolic effects on glucose and blood pressure — have emerged as active research areas over the past three decades. In 2026, melatonin occupies a unique regulatory position globally: in the United States, it is classified as a dietary supplement and available without prescription at virtually any pharmacy, grocery store, or online retailer, in doses ranging from micrograms to 20mg. In Europe, the UK, Australia, and several Asian countries, melatonin is a prescription-only medication (brand names Circadin for adult primary insomnia, Slenyto for pediatric insomnia in autism spectrum disorder), reflecting those regulators' assessment that it is a hormone rather than a nutritional supplement. In popular supplement culture, melatonin is often framed simply as a "sleep aid," but this framing substantially understates both its mechanism and its appropriate use cases. Melatonin is not primarily hypnotic in the pharmacological sense of sedatives like benzodiazepines, Z-drugs, or antihistamines — those compounds produce sleep by direct suppression of arousal systems. Melatonin instead acts as a chronobiotic, shifting the timing of the circadian pacemaker in the suprachiasmatic nucleus (SCN) and creating a biological "signal for night" that allows downstream sleep-promoting processes to operate. The implications are significant: melatonin is most effective when timing is precisely aligned with the user's target sleep phase rather than maximal dose, and it is most useful for circadian rhythm disorders (delayed sleep phase syndrome, jet lag, shift work, non-24-hour sleep-wake disorder in blind individuals, free-running disorder, REM sleep behavior disorder) rather than for primary insomnia in the pharmacological sense. The clinical evidence base is strongest and most consistent for: (1) jet lag — where multiple meta-analyses including Herxheimer & Petrie 2001 Cochrane review (PMID: 11686978) document strong efficacy when taken at bedtime in the destination time zone for eastward travel across >5 time zones; (2) delayed sleep phase syndrome (DSPS), where low-dose evening melatonin taken 5-7 hours before habitual sleep onset produces phase advances; (3) pediatric sleep disorders in children with autism spectrum disorder and ADHD, where multiple randomized trials and meta-analyses (Rossignol & Frye 2011, PMID: 21518346) document clear benefit for sleep onset latency and total sleep time; (4) REM sleep behavior disorder (RBD), where melatonin 3-12mg at bedtime reduces dream enactment episodes and is often preferred to clonazepam for older adults (Boeve et al. 2003, PMID: 14592324); (5) non-24-hour sleep-wake disorder in totally blind individuals, where entrainment to the 24-hour day is achieved by carefully-timed evening melatonin. Evidence is moderately positive for primary insomnia sleep onset latency (meta-analyses including Ferracioli-Oda et al. 2013 in PLOS One, PMID: 23691095, show modest but statistically significant reductions in sleep onset latency of approximately 7-12 minutes on average, smaller than typical hypnotic effects but clinically meaningful for some individuals), shift-work adaptation, migraine prophylaxis (Gonçalves et al. 2016, PMID: 27165014, showed melatonin 3mg nightly non-inferior to amitriptyline 25mg for chronic migraine prevention), and as an adjunct in blood-pressure management. Evidence is preliminary but compelling for melatonin as an adjunct in selected oncology protocols (particularly hormone-sensitive breast, prostate, and gastrointestinal cancers where meta-analyses including Seely et al. 2012, PMID: 22271573, suggest survival benefit when combined with standard therapy), for COVID-19 adjunctive care, and for pre-operative anxiolysis in pediatric surgery. Evidence is mixed or unclear for general anxiolysis, weight management, and fertility support — claims that circulate in supplement culture but lack strong clinical backing. A distinguishing feature of melatonin compared to other sleep aids is its extraordinarily wide safety margin and minimal abuse potential. Unlike benzodiazepines or Z-drugs, melatonin produces no physiological tolerance or dependence, does not suppress REM sleep architecture, does not impair next-day cognitive performance at appropriate doses, and has been used clinically in doses up to 300mg/day for certain oncology indications without serious acute toxicity. However, the practical sleep-supplement literature has been progressively revealing that most over-the-counter melatonin doses (3mg, 5mg, 10mg) are 10-30× higher than needed for sleep effects and that higher doses paradoxically produce worse outcomes via morning grogginess, nightmare frequency, and receptor desensitization. The current physiological-replacement approach — 0.3-1mg taken 30-60 minutes before desired sleep onset — is more effective than megadoses for most primary insomnia and sleep-timing applications. See also Ashwagandha, L-theanine, Magnesium, Glycine, 5-HTP, and Vitamin D for adjacent sleep and circadian support compounds. This overview is educational only and is not medical advice — melatonin is a hormone with metabolic, reproductive, immune, and chronobiotic effects, and extended high-dose use warrants physician consultation.

Also known as: Aminoacetic acid, Glycocoll, G, Gly, L-Glycine, Glycin, Aminoessigsäure

Glycine is the simplest amino acid—a single hydrogen atom replacing the typical side chain found in other proteinogenic amino acids—yet it performs an wide range of biological functions. Despite being classified as "non-essential" because humans can synthesize it endogenously from serine and other precursors, mounting evidence suggests glycine is conditionally essential: the synthetic capacity of human tissues falls short of daily functional demands, particularly during periods of stress, injury, aging, and rapid growth. This gap between synthesis and requirement makes dietary glycine practically important, and supplemental glycine emerges as one of the most evidence-based, low-cost, and versatile compounds in the foundational nutrition category. Glycine's biological roles span multiple major categories. It is the most abundant amino acid in collagen, comprising approximately one-third of collagen's amino acid residues (every third residue in the collagen triple helix must be glycine because the small side chain is the only one that fits at the helix interior). It serves as the primary inhibitory neurotransmitter in the spinal cord and brainstem (via glycine receptors), while also acting as an obligatory co-agonist for NMDA glutamate receptors throughout the brain. It is required for synthesis of glutathione (the body's master antioxidant), creatine (for energy metabolism), heme (for oxygen transport), bile acids (for fat digestion), and nucleotide bases (for DNA). It regulates one-carbon metabolism through the glycine cleavage system. It modulates immune function through glycine-gated chloride channels on macrophages and neutrophils. It stabilizes cell membranes, supports detoxification of many xenobiotics, and participates in the transamination reactions central to nitrogen metabolism. Given this biological breadth, it is perhaps not surprising that glycine supplementation has shown benefits across diverse clinical contexts: improved sleep quality (particularly subjective measures and early-night sleep), enhanced glutathione status in aging adults (the basis of the GlyNAC protocol), reduced symptoms in schizophrenia when combined with standard antipsychotics, improved glycemic control in type 2 diabetes, better outcomes after surgery and trauma, improved outcomes in chronic kidney disease, and potentially benefits for skin and joint health via collagen support. Dietary glycine comes primarily from collagen-containing foods—bone broth, slow-cooked meats with connective tissue, skin-on poultry and fish, gelatin desserts, and collagen supplements. Modern dietary patterns, which favor boneless skinless muscle meats over whole-animal consumption with connective tissue, deliver much less glycine than ancestral diets or traditional cuisines. A typical adult on a modern American diet consumes approximately 1.5-3 g glycine daily; Meléndez-Hevia and colleagues (PMID 19565307) calculated that the body's daily glycine requirement for collagen synthesis alone exceeds 10 g, and total requirement across all functions likely exceeds 15 g daily. This substantial gap is typically filled by endogenous synthesis, but synthetic capacity appears limited, particularly with aging and disease states. Supplementation of 3-10 g daily closes this gap conveniently and inexpensively. For users of BodyHackGuide, glycine represents one of the most underrated foundational supplements. The cost is trivial (pure glycine powder is among the cheapest supplements per gram), the taste is pleasantly sweet (making it easy to consume), the safety profile is excellent (human supplementation doses of 30+ g daily have been tested without significant adverse effects), and the evidence base spans sleep, glutathione/aging biomarkers, glycemic control, and connective tissue support. Common supplementation errors include: (1) assuming glycine effects will be rapid and dramatic—most benefits emerge over weeks of consistent use, (2) mixing up glycine with glucine or other unrelated compounds, (3) using inadequate doses (under 3 g daily often shows minimal effect on sleep), and (4) neglecting dietary sources of glycine in favor of supplementation when both are straightforward. This monograph addresses each of these issues with the specificity needed for informed self-experimentation. For related foundational support, see /compound/creatine, /compound/taurine, /compound/magnesium, and /compound/nac.

Also known as: gamma-glutamylethylamide, N-ethyl-L-glutamine, γ-L-glutamylethylamide, Suntheanine, Theanine

L-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack. Chemically L-theanine is γ-glutamylethylamide (N-ethyl-L-glutamine), a structural analog of the excitatory neurotransmitter glutamate and its inhibitory cousin GABA — close enough to both to interact with their transporters and, at high doses, their receptors, but distinct enough to produce a characteristic combination of reduced sympathetic arousal, mildly enhanced alpha-wave EEG activity, and preserved or modestly improved attention that the literature has consistently tied to its single signature phrase: "relaxed alertness." The modern L-theanine literature traces back to Japanese tea-chemistry research in the 1950s — theanine was first isolated from green tea by Sakato in 1949 — but its Western nootropic adoption is much more recent, anchored by three key human studies: Kobayashi et al. 1998 (Japanese EEG study, alpha-wave elevation at 50-200mg oral doses), Haskell et al. 2008 (Biological Psychology PMID: 18006208), which showed that 100mg L-theanine + 50mg caffeine produces faster attention-task reaction times and subjectively better mood than either compound alone, and Kimura et al. 2007 (Biological Psychology PMID: 16930802), which demonstrated that 200mg L-theanine reduces heart rate and salivary immunoglobulin A responses to an acute stress task — the cleanest human physiology demonstration of its anxiolytic effect. Supporting RCTs include Hidese et al. 2019 (Nutrients, 4-week 200mg/day for stress and sleep in healthy adults) and Lyon et al. 2011 (Alternative Medicine Review, 200mg BID improving sleep quality in boys with ADHD). Pharmacologically, L-theanine crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1), reaching brain tissue within 30-60 minutes of an oral dose. It has a plasma half-life of roughly 1-3 hours in humans, with central nervous system exposure outlasting plasma, and it acts on multiple neurotransmitter systems simultaneously (glutamate, GABA, dopamine, serotonin, catecholamines) — but at physiologic supplement doses its effects on any single system are modest. It is a weak, broadly-acting modulator rather than a strong selective agent. This is why it does NOT cause sedation, dependence, tolerance, or rebound the way GABAergic sedatives (phenibut, benzodiazepines, Z-drugs) do — you can take 200mg daily for years without tolerance development. The largest user population is the caffeine-stack crowd — knowledge workers, students, coders, writers — taking 100-200mg caffeine daily for alertness and wanting to take the edge off the jitter without losing the focus boost. The canonical stack is 200mg caffeine + 200mg L-theanine taken together once in the morning. A second population uses it for acute stress (200mg, 30-60 minutes before a stressful event). A third cohort uses 400-600mg for schizophrenia-adjunctive anxiety based on the Ritsner 2011 data (PMID: 21208586). A fourth uses 200-400mg at bedtime for sleep quality, though the adult sleep evidence is weaker than the ADHD-boys data from Lyon 2011. Where L-theanine does NOT work: it is not a sedative, not a cognitive enhancer in isolation (the attention benefit shows up only when paired with caffeine), not a panic-attack abortive, not an SSRI substitute for clinical depression or GAD, and not equivalent to meditation or therapy for chronic anxiety. Safety profile stands out: FDA-GRAS since 2007 as Suntheanine®, rodent LD50 >5 g/kg (effectively unreachable at oral doses), decades of dietary human exposure through green tea, no dependence or withdrawal reported in any RCT. Side effects (mild headache, GI upset, dizziness at high doses) occur at placebo-comparable rates. The only meaningful practical cautions are possible additive hypotensive effect with blood-pressure medications and theoretical interaction with stimulant medications (though theanine + stimulant combinations are actually commonly used and well-tolerated). L-theanine pairs well with nearly everything. The caffeine pair is canonical. Ashwagandha is increasingly common for daytime anxiolysis. Magnesium glycinate or L-threonate pairs for evening use. Rhodiola rosea + L-theanine + caffeine is a strong "calm focus + adaptogen" stack. Avoid stacking with strong sedatives (benzodiazepines, high-dose kava, phenibut in naive users) — not because of a specific interaction but because the subjective synergy blunts the productive-calm signature L-theanine is typically used for. This is educational content and not medical advice; L-theanine is exceptionally safe for most healthy adults but blood-pressure medications, antipsychotics, and pregnancy/pediatric use warrant physician input before supplementation.

Also known as: Tryptophan, L-Trp, Trp, (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid

L-Tryptophan is one of the nine essential amino acids — meaning the human body cannot synthesize it and must obtain it from dietary protein — and is the direct metabolic precursor to serotonin, melatonin, and (via a separate route) the vitamin niacin (nicotinamide / NAD+). It is the least abundant essential amino acid in most protein sources, and its selective depletion has been used for decades as a research tool to probe the role of serotonin in mood, cognition, and aggression. As a dietary supplement it sits at an unusual intersection: foundational nutrient, serotonin precursor, sleep aid, and the compound at the center of one of the most consequential supplement safety events in US regulatory history — the 1989 eosinophilia-myalgia syndrome (EMS) outbreak that killed roughly 37 people and sickened ~1,500, which was eventually traced to contaminants in a single manufacturer's bulk product (Showa Denko). That tragedy drove an FDA import alert and a near-total disappearance of tryptophan from the US supplement market for over a decade; it has since returned under USP-verified, third-party-tested sourcing, but the shadow of EMS continues to shape how cautious clinicians and regulators think about the compound. Chemically, L-tryptophan is (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid — an aromatic amino acid defined by its indole ring, a bicyclic nitrogen-containing aromatic structure that is also the structural core of serotonin, melatonin, psilocin, DMT, and a wide family of indoleamine neuromodulators. The indole ring is what makes tryptophan fluorescent and what makes it the most spectroscopically distinctive amino acid in proteins. In dietary terms, it is abundant in turkey, chicken, eggs, cheese, fish, pumpkin seeds, soybeans, oats, and dairy — contrary to popular folklore, turkey is not unusually rich in tryptophan relative to other protein sources, and the post-Thanksgiving drowsiness attributed to turkey's tryptophan is more plausibly a function of carbohydrate-induced insulin release shunting competing large neutral amino acids into muscle, plus a large meal, plus alcohol, plus the parasympathetic lull of a long family dinner. The supplemental rationale for L-tryptophan is tied almost entirely to its role as a precursor. Ingested tryptophan is absorbed in the small intestine, enters circulation, crosses the blood-brain barrier in competition with other large neutral amino acids (LNAAs) — leucine, isoleucine, valine, phenylalanine, tyrosine, methionine — and is converted in serotonergic neurons by tryptophan hydroxylase (TPH1 in the gut/periphery, TPH2 in the brain) to 5-hydroxytryptophan (5-HTP), which is then decarboxylated by AADC to serotonin (5-HT). Serotonin in the pineal gland is subsequently acetylated (by AA-NAT) and methylated (by HIOMT) to produce melatonin, the circadian-aligned sleep-promoting hormone. Only a small fraction of dietary tryptophan — typically cited as ~1-5% — follows this serotonin/melatonin path; the vast majority (~95%) is shunted through the kynurenine pathway via tryptophan 2,3-dioxygenase (TDO) in the liver or indoleamine 2,3-dioxygenase (IDO) in immune and peripheral tissues, generating kynurenine and a cascade of downstream metabolites (kynurenic acid, quinolinic acid, xanthurenic acid, picolinic acid) that feed into NAD+ synthesis and immune signaling. The kynurenine pathway is itself a topic of intense contemporary research — kynurenic acid is a glycine-site NMDA antagonist and α7-nicotinic antagonist (possibly neuroprotective), while quinolinic acid is an NMDA agonist and has been linked to depression, neuroinflammation, and neurodegeneration. The historical context for tryptophan supplementation starts in the 1970s, when early sleep researchers — notably Ernest Hartmann at Boston State Hospital — reported that 1-4 grams of oral tryptophan reduced sleep latency in mild insomniacs without the "morning-after" grogginess associated with benzodiazepines. Through the 1980s, tryptophan was widely used for sleep, mood, and pre-menstrual symptoms across North America, sold as a dietary supplement in health food stores. In 1989, clusters of a new and frightening syndrome — severe eosinophilia, disabling myalgia, fasciitis, neuropathy — were reported from New Mexico and rapidly traced to L-tryptophan supplementation (Belongia et al. 1990, NEJM PMID: 2370676). Epidemiological investigation pinned the cases to bulk tryptophan manufactured by Showa Denko in Japan using a specific modified fermentation strain; contaminants (EBT, "peak E", plus related impurities) — not tryptophan itself — were the likely causative agents. FDA imposed an import alert; by 1990 tryptophan was effectively off US shelves. The import alert was relaxed in 2001-2005 as USP-verified sourcing and improved analytical methods allowed regulators to reintroduce the product; since then, L-tryptophan has been legally available in the US as a dietary supplement, but with ongoing emphasis on third-party testing and USP verification precisely because of the EMS legacy. Current use is concentrated in three buckets: (1) sleep latency support — the original Hartmann-era indication; modest but real effect in mild insomnia (Silber & Schmitt 2010 PMID: 19887142, review); (2) mood support — particularly in acute tryptophan depletion research (Young 2013 PMID: 22889546) showing that depleting tryptophan rapidly reproduces low mood in people with a history of depression, supporting a causal role for serotonin availability; clinical response to supplemental tryptophan in actual depression is mixed; (3) niche applications — PMS symptoms, post-partum blues, aggression/irritability, carb-craving. Dosing is typically 500mg to 3g/day, often at bedtime or split. Onset for acute effects is ~30-90 minutes; steady-state serotonergic effects may take 1-2 weeks. Who uses it and why — the practical picture — breaks down roughly as: people who want a gentler alternative to 5-HTP (tryptophan is upstream of the TPH rate-limit and therefore subject to homeostatic regulation that 5-HTP bypasses); people whose melatonin use has plateaued or who want endogenous melatonin support rather than exogenous dosing; people exploring serotonergic support without prescription SSRIs; and a smaller group using tryptophan as an aggression/irritability-reducing intervention (this has modest RCT support). If you're comparing this to 5-HTP, here's the tradeoff: tryptophan is the upstream amino acid subject to TPH regulation (harder to overshoot, gentler effect), while 5-HTP bypasses TPH and converts directly to serotonin (faster, more potent, but with more room to overshoot into serotonin syndrome territory when combined with serotonergic drugs). For most self-experimenters, tryptophan is the safer starting point. See also 5-HTP, Melatonin, SAM-e, Magnesium, L-Theanine, Ashwagandha, Rhodiola, Lithium Orotate, and Lion's Mane for adjacent serotonergic, sleep-supportive, and mood-supportive compounds commonly used in the same stacks. This is educational content and not medical advice — tryptophan supplementation has real interactions with prescribed serotonergic medications (SSRIs, MAOIs, triptans, tramadol, dextromethorphan) and warrants physician-level guidance when those are in play.

Also known as: Mg, Mg2+, Magnesium citrate, Magnesium glycinate, Magnesium bisglycinate, Magnesium malate, Magnesium taurate, Magnesium L-threonate, Magnesium oxide, Magnesium chloride, Magnesium sulfate, Magnesium orotate, Magnesium lactate, Epsom salt

Magnesium is the fourth most abundant cation in the human body and the second most abundant intracellular cation after potassium, with approximately 25 grams present in a typical adult—roughly 60% stored in bone, 27% in muscle, 6-7% in other soft tissues, and less than 1% in extracellular fluid including serum. Despite this substantial total-body load, magnesium deficiency is extraordinarily common in modern populations: national survey data from the United States (DiNicolantonio et al., PMID 29387438; Rosanoff et al., PMID 22365240) suggests that roughly half of adults consume below the estimated average requirement, and a meaningful fraction—perhaps 10-30% depending on the criterion used—show biochemical evidence of frank deficiency. The prevalence is even higher among patients with type 2 diabetes, alcohol use disorder, heart failure, chronic proton pump inhibitor users, loop/thiazide diuretic users, and elderly adults with reduced appetite or impaired intestinal absorption. Because serum magnesium (the most commonly ordered clinical test) measures only that <1% extracellular fraction and is tightly defended by bone mineral release and renal reabsorption even when cellular stores are depleted, normal serum magnesium does not rule out functional deficiency. Many researchers argue that the reference range itself is set too low, rooted in population distributions that already reflect widespread subclinical deficiency. Magnesium functions as a required cofactor for more than 600 enzymatic reactions (Gröber et al., PMID 26404370)—essentially every reaction involving ATP, because the bioactive form of ATP is the Mg-ATP complex and free ATP has negligible biological activity. This places magnesium at the center of energy metabolism, protein synthesis, DNA and RNA synthesis, oxidative phosphorylation, glucose utilization, and cellular electrolyte homeostasis. Beyond its cofactor roles, magnesium is a physiological calcium channel antagonist: it competes with calcium at voltage-gated calcium channels in smooth muscle, cardiac conducting tissue, and neurons, which explains its effects on vascular tone, cardiac rhythm, neuromuscular excitability, and neuronal signaling. Magnesium also voltage-gates the NMDA glutamate receptor in the central nervous system—one of the fundamental mechanisms of synaptic plasticity and learning, and a key point of regulation in pain signaling, seizure thresholds, and mood. Supplemental magnesium is among the most thoroughly studied nutrient interventions in clinical medicine. Randomized trials and meta-analyses demonstrate meaningful effects on blood pressure (Zhang et al., PMID 27402922), insulin sensitivity and glycemic control in type 2 diabetes (Guerrero-Romero, PMID 21127832; Rodríguez-Morán and Guerrero-Romero, PMID 12663588), migraine frequency (Peikert et al., PMID 8792038; Facchinetti et al., PMID 1860787; Mauskop review, PMID 29314056), sleep quality in older adults (Abbasi et al., PMID 23853635), leg cramps in late-pregnancy and general populations (mixed evidence), depression symptoms (Tarleton et al., PMID 28654669), and muscle performance. Observational evidence associates higher magnesium intake with lower all-cause mortality, lower cardiovascular disease incidence, lower stroke risk, lower risk of type 2 diabetes, and better bone mineral density. Magnesium is also a first-line intravenous intervention for preeclampsia/eclampsia (MgSO4), torsades de pointes, severe asthma exacerbation, and certain arrhythmias—uses that reflect strong hospital-setting evidence but are distinct from routine oral supplementation. Commercial magnesium supplements span a confusing landscape of salts—citrate, glycinate (also called bisglycinate), malate, taurate, L-threonate, oxide, chloride, sulfate, orotate, lactate, aspartate, carbonate, hydroxide—with meaningfully different bioavailability profiles, elemental magnesium content per gram, tolerability, and tissue-specific effects. Magnesium oxide, despite being the cheapest and most common in drugstore multivitamins, has poor bioavailability (perhaps 4% absorbed in some studies) and tends to produce diarrhea. Magnesium glycinate and bisglycinate are generally regarded as among the best-tolerated forms for doses above a few hundred milligrams, with smooth absorption and minimal GI effect. Magnesium L-threonate is the only form with clinical trial evidence for brain-penetrant effects on memory and cognition (Liu et al., PMID 25589719) and is marketed as Magtein. Magnesium taurate combines two cardioprotective minerals and is particularly favored for cardiovascular indications. Magnesium malate may benefit muscle energy metabolism via the malate-aspartate shuttle. The "best" form depends on the goal: sleep and general repletion favor glycinate or citrate; constipation relief favors citrate or oxide; migraine prophylaxis was studied mainly with citrate (600 mg trivalproate equivalents) or oxide; cognition research favors L-threonate; cardiovascular goals may favor taurate. For BodyHackGuide users, magnesium is a cornerstone of any rational supplementation stack. The cost-to-benefit ratio is exceptional: for a few dollars monthly, users correct a common subclinical deficiency and gain measurable improvements in sleep latency, stress resilience, bowel regularity, blood pressure, and exercise recovery. The safety margin is wide for healthy adults with normal renal function. Yet many users either take too little (100-200 mg oxide from a multivitamin, poorly absorbed, insufficient to raise cellular stores) or take the wrong form for their goal. This monograph addresses form selection, dose titration, timing, stacking, and the specific clinical scenarios where magnesium supplementation is best evidenced. For related foundational support, see /compound/vitamin-d (reciprocal activation with magnesium in converting 25(OH)D to 1,25(OH)2D), /compound/zinc (another ubiquitously deficient mineral), /compound/taurine (synergy in magnesium taurate), /compound/glycine (synergy in magnesium glycinate), and /compound/creatine (ATP-dependent metabolism where magnesium is the counter-ion).

Also known as: Magtein, L-Threonic Acid Magnesium Salt, MgT, Magnesium-L-Threonate, L-TAMS, Mg L-Threonate

Magnesium L-Threonate is a proprietary chelated form of magnesium in which the magnesium cation is bound to L-threonic acid — a metabolite of ascorbic acid (vitamin C) — forming the salt commonly marketed under the brand name Magtein. It was developed in the mid-2000s by researchers associated with MIT (notably Guosong Liu, then at the MIT Department of Brain and Cognitive Sciences) with the explicit goal of producing a magnesium compound that could meaningfully raise brain magnesium concentrations in a way that ordinary oral magnesium salts (oxide, citrate, glycinate, malate, chloride) have historically struggled to accomplish. The resulting molecule was commercialized through Magceutics and Neurocentria, and Magtein is now the dominant ingredient in cognition-oriented magnesium products marketed to consumers. The clinical rationale behind magnesium L-threonate rests on a specific biological problem: magnesium is a physiological NMDA glutamate receptor antagonist — a voltage-dependent blocker that sits in the NMDA channel pore and regulates excitatory neurotransmission — yet CNS magnesium concentrations are tightly defended and do not readily rise in response to oral supplementation with most common magnesium forms. Even substantial oral dosing of magnesium oxide or citrate (often 400mg elemental or more daily) may produce modest serum changes without corresponding cerebrospinal fluid (CSF) or brain extracellular magnesium elevation. This is not merely a theoretical concern — it implies that people using conventional magnesium supplements for cognitive, sleep, anxiety, or mood benefits may be relying partly on peripheral effects and on small central effects that are difficult to measure and potentially limited in magnitude. Slutsky et al. 2010 (Neuron PMID: 20152124) — the landmark MIT paper — demonstrated that L-threonate conjugation allows magnesium to raise brain magnesium concentrations in rats in a way that other forms did not, and that this elevation translated into upregulated synaptic density, enhanced LTP (long-term potentiation), and improved behavioral measures of learning and memory in aged animals. This rat paper remains the single most cited justification for preferring Magtein over other magnesium forms for cognitive applications. Translated human evidence is substantially thinner than the mechanistic rat data. Liu et al. 2016 (Journal of Alzheimer's Disease PMID: 26600199) — the only decent human RCT published as of this writing — enrolled 44 older adults (ages 50-70) with cognitive impairment and randomized them to 12 weeks of Magtein (1.5-2 grams/day providing approximately 144-192mg elemental magnesium) or placebo. The trial reported improvements on a composite cognitive score that the authors interpreted as a reduction in "brain age" by approximately 9 years. Results were favorable but the study was small, industry-sponsored (funded by Magceutics), and independent replication has been weak — a point that matters for a supplement marketed with confident claims about cognition, memory, and "brain age." Users and practitioners should weigh that single decent RCT carefully: it is the most promising human data we have, but one small industry-funded trial is not a strong evidence base for the specific cognitive claims routinely made about Magtein in consumer marketing. Subsequent small trials have examined anxiety, sleep, and subjective cognitive symptoms with mixed and generally modest findings. Why people actually take magnesium L-threonate in practice usually comes down to a few overlapping use cases: (1) cognitive support — particularly older adults or people concerned about age-related cognitive decline, based on Slutsky 2010 and Liu 2016; (2) sleep — evening dosing is commonly reported to improve subjective sleep quality, though this overlap substantially with non-specific benefits of magnesium repletion that are equally achievable with much cheaper Magnesium glycinate; (3) anxiety — systematic reviews of magnesium and anxiety (Pickering 2020 PMID: 32210180) pool across many forms and find modest positive effects, but threonate-specific anxiety data are limited; (4) general magnesium repletion with a cognition halo — some users take Magtein as their primary magnesium source while hoping to capture both general repletion and specific CNS effects. A practical point up front: Magtein delivers relatively little elemental magnesium per dose. The typical 1.5-2g/day Magtein dose provides ~144-192mg elemental magnesium — considerably less than a standard magnesium glycinate dose (200-400mg elemental at a fraction of the cost). For systemic magnesium repletion (muscle cramps, constipation, blood pressure, general wellness), glycinate is equivalent or superior and substantially cheaper. Magtein's proposed advantage is narrowly about CNS magnesium elevation for cognitive applications. Users often combine Magtein with another cheaper magnesium form to hit general elemental targets; relying on Magtein alone for both CNS and general repletion rarely pencils out. The commercial landscape also warrants attention. "Magnesium threonate" products fall into two broad categories: Magtein-branded (certified through Magceutics/Neurocentria licensing, defined L-isomer specifications, third-party testing) and generic "magnesium threonate" (uncertain L-isomer purity, not studied in the published clinical research). The published evidence applies specifically to Magtein; this distinction is often glossed over in consumer marketing and price differences typically reflect it. See also Magnesium, Lion's Mane, Creatine, Citicoline, Acetyl-L-Carnitine, Bacopa, Phosphatidylserine, and Fisetin for adjacent cognitive-support and magnesium-related compounds commonly used in nootropic stacks. This is educational content and not medical advice — magnesium supplementation is generally safe but clinical applications (particularly in renal impairment, in children, or with drug-interacting medications) warrant physician-level guidance.

Also known as: Apigenin, 4',5,7-Trihydroxyflavone, 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, Chamomile flavone, Parsley apigenin, Celery apigenin, Apigenol, Versulin, Spigenin

Apigenin is a plant-derived flavone (4',5,7-trihydroxyflavone) that occurs widely in the plant kingdom as a constituent of leaves, flowers, and seeds. Structurally it is a flavone — distinguished from flavonols like quercetin and fisetin by the absence of a 3-hydroxyl group — giving it a simpler hydroxylation pattern with hydroxyl groups only at positions 4', 5, and 7. This structural simplicity underlies some of apigenin's distinctive biological properties, particularly its activity at GABA-A receptors (relevant to chamomile's traditional use as a calming herb) and its distinct profile of anticancer activity in preclinical studies. Apigenin is most concentrated in parsley (dried parsley contains up to 45 mg/g — exceptional by polyphenol standards), chamomile flowers and tea (approximately 5-16 mg/g dried chamomile flowers), celery (particularly the leaves), artichokes, and certain other culinary herbs. Other dietary sources with measurable apigenin content include oranges, grapefruit, onions, olives, and some teas. A standard cup of chamomile tea provides approximately 1-2 mg of apigenin, while dietary intake from parsley-rich Mediterranean cuisine may reach several mg daily. Typical Western dietary intake of apigenin averages below 1 mg per day, far below supplementation doses associated with claimed biological effects (50-500 mg daily). Modern scientific interest in apigenin derives from several converging lines of research. First, traditional herbal medicine has used chamomile (Matricaria chamomilla) for anxiolytic and calmative effects for centuries, and apigenin was identified as one of the key bioactive constituents responsible for these effects, with documented binding to benzodiazepine binding sites on GABA-A receptors. Second, a 2013 paper by Escande and colleagues (PMID 23603845) identified apigenin as an inhibitor of CD38 — the enzyme responsible for degrading NAD+ in mammalian cells — proposing apigenin as a tool for raising intracellular NAD+ levels by preventing NAD+ consumption. This work positioned apigenin as a complement to NAD+ precursors like nicotinamide riboside and nicotinamide mononucleotide. Third, extensive preclinical research has documented apigenin's anticancer effects in multiple tumor models, with mechanisms spanning cell cycle arrest, apoptosis induction, inhibition of angiogenesis, and modulation of inflammatory and growth factor signaling. Key scientific work includes Escande 2013 (PMID 23603845) demonstrating apigenin as a CD38 inhibitor with IC50 in the low micromolar range and showing in mice that apigenin administration elevated intracellular NAD+ levels in multiple tissues including liver, muscle, and white adipose tissue. Shukla and colleagues have extensively studied apigenin in prostate cancer models including Shukla 2014 (PMID 24957915) demonstrating efficacy in TRAMP mice. Camacho-Alonso 2019 (PMID 30904672) and related work addressed head and neck cancer applications. Gradolatto 2005 (PMID 15887220) characterized apigenin's oral pharmacokinetics in rats. Meyer 2006 (PMID 16706750) explored apigenin's anti-inflammatory mechanisms. Pharmacokinetically apigenin has modest oral bioavailability. In rat studies, oral bioavailability of free aglycone is approximately 20-25% with extensive glucuronidation and sulfation producing circulating conjugates. Plasma half-life is approximately 90 minutes for parent compound with longer half-lives for conjugates. Tissue distribution is broad with concentrations particularly in liver, kidney, intestine, and lung. Blood-brain barrier penetration is limited but sufficient for the GABA-A effects observed with chamomile-equivalent doses. Commercial supplementation typically uses apigenin from parsley, chamomile, or Passiflora incarnata (passionflower) extracts, standardized to 95-98% apigenin content. Liposomal and phytosome formulations provide enhanced bioavailability for therapeutic applications. The thematic positioning of apigenin in longevity and health supplementation spans three complementary use cases. First, as a CD38 inhibitor and thus an NAD+ preservation agent, apigenin is used alongside NAD+ precursors (NR, NMN) in longevity-oriented protocols. Second, as a GABA-A modulator, apigenin is used for sleep, anxiety reduction, and relaxation — in both chamomile tea form and higher-dose supplementation. Third, as a chemopreventive polyphenol with broad anti-inflammatory and cell-signaling effects, apigenin joins the polyphenol stack (quercetin, fisetin, curcumin) for general longevity and anti-inflammatory purposes. No single application has strong Phase 3 human clinical trial evidence, but the combined preclinical and mechanistic case is substantial. Commercial apigenin products vary in quality and standardization. Prefer products specifying source (parsley, chamomile, passiflora), confirmed purity (>95%), and third-party testing. Apigenin phytosome or liposomal formulations are increasingly available for users pursuing higher tissue concentrations. Typical supplementation doses range from 50 mg daily (low-dose sleep/mood support) to 500 mg daily (therapeutic dose for NAD+ preservation or anti-inflammatory goals).

Also known as: Withania somnifera, Indian Ginseng, Winter Cherry, KSM-66, Sensoril, Shoden

Ashwagandha (Withania somnifera, also called "Indian ginseng" and "winter cherry") is the most studied and most clinically validated herbal adaptogen in the contemporary supplement market. It is the botanical anchor of Ayurvedic medicine — the indigenous medical tradition of the Indian subcontinent — where its Sanskrit name "ashwagandha" ("smell of horse") refers to the distinctive odor of the fresh root and alludes to the traditional belief that the root confers the strength of a horse. Ashwagandha has been used medicinally for over 3,000 years in Ayurvedic practice as a rasayana (rejuvenative), traditionally prescribed for fatigue, weakness, reproductive concerns, chronic inflammation, joint pain, and general vitality. In the past 15 years, modern clinical research has confirmed and expanded many of these traditional uses, producing one of the strongest randomized controlled trial evidence bases in the entire botanical medicine space — covering stress, anxiety, sleep, testosterone, muscle strength, cognitive function, and metabolic health. The pharmacologically active constituents of ashwagandha are a family of steroidal lactones called withanolides, structurally similar to both plant and animal sterols. The most studied withanolides are withaferin A (the most pharmacologically potent, concentrated in leaves), withanolide A, withanolide D, withanolide E, withanoside IV and VI, and the sitoindosides (VII–X). Standardized ashwagandha extracts are characterized by their total withanolide content (typically 1.5–10% by weight) and by their specific withaferin A content (which varies from trace amounts in root-only extracts to 0.5–2% in leaf-containing extracts). Two branded extracts dominate the clinical literature and commercial market: KSM-66 (Ixoreal Biomed, India — root-only extract standardized to at least 5% withanolides with very low withaferin A), and Sensoril (Natreon, India — root-plus-leaf extract standardized to at least 10% withanolides with 32% higher withaferin A content). These two branded extracts have materially different pharmacologic profiles and clinical use cases: KSM-66 has been studied predominantly for stress, cognitive, reproductive, and athletic performance indications; Sensoril has been studied for sleep, anxiety, and general adaptogen applications where the faster onset attributable to withaferin A is desired. BodyHackGuide covers ashwagandha as the first-line adaptogen for the stress-sleep-recovery axis, alongside companion agents like rhodiola rosea (a stimulating adaptogen with better acute-cognitive effects), bacopa monnieri (cognitive and memory focus), l-theanine (acute relaxation without sedation), magnesium glycinate (mineral cofactor for stress and sleep), and gotu kola (circulatory and cognitive Ayurvedic companion). Within this framework, ashwagandha is the anchor for cortisol normalization, chronic stress adaptation, sleep quality improvement, and recovery from physical and mental exertion. It is particularly valuable for users managing the "wired and tired" pattern of chronic sympathetic overactivation — elevated evening cortisol, poor sleep onset or depth, morning fatigue despite adequate sleep hours, difficulty winding down after work, and the sense of running on adrenaline rather than sustained energy. The contemporary clinical evidence base for ashwagandha includes more than 30 randomized controlled trials with mostly positive findings across four main indication clusters. First, stress and anxiety: Chandrasekhar 2012 (PMID 23439798) — the classic RCT of KSM-66 300 mg BID in 64 chronically stressed adults over 60 days, showing 28% reduction in serum cortisol, 44% reduction in perceived stress scale (PSS), and significant reductions in State-Trait Anxiety Inventory and General Health Questionnaire scores. Salve 2019 (PMID 32082747), Lopresti 2019 (PMID 31517876), and multiple subsequent RCTs have replicated the cortisol-reducing and stress-relieving effects. Second, sleep: Langade 2019 (PMID 31728244) — 600 mg/day of ashwagandha root extract in 80 non-clinical insomnia subjects over 10 weeks, showing significant improvements in sleep onset latency, total sleep time, and sleep efficiency on actigraphy, with parallel improvements in anxiety. Third, testosterone and reproductive health: Ambiye 2013 (PMID 24371462) in oligospermic males showed 17% testosterone elevation and improved sperm parameters; Lopresti 2019 Am J Mens Health (PMID 30854916) in aging overweight males showed 14% testosterone elevation and DHEA-S increase over 16 weeks; Chauhan 2022 PMID 35873404 in healthy adult males showed improvements in testosterone, sperm concentration, and vitality markers. Fourth, muscle strength and athletic performance: Wankhede 2015 (PMID 26609282) in resistance-training men showed significantly greater strength gains on bench press and leg extension, greater muscle mass gains, and reduced exercise-induced muscle damage markers with KSM-66 600 mg/day over 8 weeks compared to placebo; subsequent trials have confirmed the strength and body-composition effects, with more modest signals on endurance (Choudhary 2015 PMID 26730141). Beyond these four clusters, ashwagandha has emerging or supportive evidence in: cognitive function in aging and mild cognitive impairment (Choudhary 2017, Ng 2020, several small trials showing modest improvements in memory, processing speed, and executive function); metabolic health (modest improvements in fasting glucose, HbA1c, HOMA-IR, and lipid profile in small trials); thyroid function (trials in subclinical hypothyroidism showing mild TSH reduction and T3/T4 elevation — a double-edged effect that can help or harm depending on thyroid status); immune function (increased white blood cell count and improved mucosal immunity in small trials); and bipolar disorder and schizophrenia (small adjunct RCTs showing modest signals, though these are specialist-care contexts rather than self-directed supplement use). Commercially, ashwagandha is among the fastest-growing supplement ingredients of the past decade. Branded KSM-66 and Sensoril extracts dominate the quality tier of the market, appearing in products from Thorne, Life Extension, Jarrow Formulas, NOW Foods, Pure Encapsulations, Designs for Health, Himalaya, and dozens of sports nutrition and wellness brands. Typical formulations: KSM-66 at 600 mg/day (300 mg BID or as a single evening dose), Sensoril at 125–250 mg/day (usually single daily dose), or generic standardized ashwagandha at 300–600 mg/day of a 5% withanolide extract. Quality varies substantially: non-standardized "ashwagandha root powder" bulk capsules bear little resemblance to the clinical-trial standardized extracts and should generally be avoided for therapeutic intent. Cost for branded extracts: roughly $15–30 per month depending on dose and retailer. Ashwagandha is best understood as a foundational daily-use adaptogen for modern stress physiology. It is not a sedative (it does not cause drowsiness during the day), not a stimulant (it does not produce the alertness of caffeine or rhodiola), and not an acute anxiolytic (it does not produce benzodiazepine-like rapid anxiety reduction). It is, instead, a slow-acting HPA-axis modulator that reduces baseline cortisol, improves stress-response resilience, supports sleep quality, and enables recovery from sustained physical and mental exertion over weeks to months of consistent use. For BodyHackGuide users managing chronic stress, sleep disruption, recovery demands from training, or the generalized symptoms of hyper-aroused modern life, ashwagandha is the single most defensible adaptogen choice with the strongest clinical evidence base and a favorable safety profile across most populations.

Also known as: EDR

Pinealon is a synthetic tripeptide — glutamyl-aspartyl-arginine (Glu-Asp-Arg, or EDR) — developed by the St Petersburg Institute of Bioregulation and Gerontology (IBG) under the leadership of Professor Vladimir Khavinson, the dominant figure in what is collectively known as the "Russian short-peptide bioregulator" school of research. Pinealon was designed as a peptide analog of signaling molecules found in natural extracts of the pineal gland, specifically a class of bioactive compounds that Khavinson's group began isolating and characterizing in the late 1980s as "cytomedins" — short peptides extracted from specific animal tissues and claimed to carry tissue-specific regulatory signals back to the corresponding tissue type. The Khavinson framework is as follows: the pineal gland, like other endocrine and parenchymal organs, contains short regulatory peptides that are involved in cell differentiation, gene expression regulation, and tissue homeostasis. When these natural peptides are purified, sequenced, and synthetic analogs are produced (the short-peptide analogs being the most studied), the synthetic peptides retain the ability to influence the same tissue from which they were derived. Pinealon, as the pineal-derived tripeptide bioregulator, is claimed to act on neural tissue — particularly the brain — to support neuroprotection, cognitive function, circadian regulation, and protection against age-related neurodegeneration. A substantial body of Russian-language clinical and preclinical literature supports these claims, going back to the 1990s and continuing through 2026. The work has been led by Khavinson and his collaborators at the Mechnikov North-Western State Medical University in St Petersburg, published in Russian medical journals (Uspekhi Gerontologii, Bulletin of Experimental Biology and Medicine) and selected Western journals (Neuroendocrinology Letters, Biogerontology). Outside Russia, Pinealon is part of a broader group of short-peptide bioregulators that includes Epitalon, Thymogen, Thymalin, Vilon, Livagen, and others — each claimed to be organ-specific based on the source tissue of the original natural peptide extract. The Western biomedical community has given Khavinson's work a mixed reception. On the positive side, the theoretical framework — that short peptides could function as tissue-specific gene-expression modulators — is scientifically coherent, and a subset of the claims (particularly around Epitalon and telomere biology) has attracted genuine interest and some independent replication. On the skeptical side, the clinical datasets are predominantly Russian, the independent replication of the most dramatic outcomes is thin, the peptides have never been through standard Western regulatory approval processes, and the commercial availability in Russia through the "Cytogen" brand (Cytomed) and various gerontology clinics has driven a significant body-hacking export market without corresponding Western clinical validation. This entry takes the honest position that Pinealon — and the broader Russian short-peptide bioregulator category — represents a plausible mechanism of action with real Russian clinical use, limited Western replication, and a research-grade user experience outside Russia. It is not FDA-approved, not widely available through Western prescription pharmacies, and carries the full research-chemical status in most Western jurisdictions. Users engaging with Pinealon are effectively trusting Khavinson's lab and its affiliated clinical collaborators, without the standard Western regulatory and replication infrastructure. For readers exploring the Khavinson peptide space, see also Epitalon, Thymogen, Cartalax, Vilon, and related entries. For comparison with other short-peptide neuroprotective compounds, see Cerebrolysin (a larger neuropeptide preparation), Semax (Russian ACTH-derived peptide), and Selank.

Also known as: Myo-inositol, D-chiro-inositol, DCI, Cyclohexanehexol, Vitamin B8 (historical, now disputed), meso-inositol, Inofolic, Inofolic Plus

Inositol is a naturally-occurring cyclic sugar alcohol (cyclohexanehexol) that functions as a critical structural component of cell membranes and a second-messenger precursor in intracellular signaling. Of the nine possible stereoisomers of inositol, only two — myo-inositol (myo-I) and D-chiro-inositol (DCI) — have significant biological activity in human physiology. These two isomers serve complementary roles: myo-inositol is the dominant form (~99% of tissue inositol), supports phosphatidylinositol signaling and serves as the precursor for inositol polyphosphates (IP3, IP4, etc.) that mediate insulin signaling and calcium release; D-chiro-inositol is a minor form (~1%) but has distinct insulin-related effects including roles in glycogen synthesis and lipid metabolism. The body synthesizes ~4 grams/day of inositol endogenously from glucose (primarily in kidneys) and obtains additional inositol from diet (fruits, beans, grains, nuts), so frank inositol deficiency is rare in healthy adults. However, supplemental inositol at pharmacologic doses (2-18g/day) produces substantial clinical effects that are used therapeutically across several domains including polycystic ovary syndrome (PCOS), insulin resistance and metabolic syndrome, anxiety and panic disorders, obsessive-compulsive disorder, depression, gestational diabetes prevention, and fertility/IVF tuning. The therapeutic history of inositol supplementation reflects parallel lines of research in psychiatry and reproductive endocrinology. In psychiatry, Levine et al. 1995-1997 and Fux et al. 1996, 1999 (PMIDs: 8780423, 10071466) established that high-dose oral myo-inositol (12-18g/day) produces anxiolytic effects equivalent to fluvoxamine (Luvox, an SSRI) for panic disorder and agoraphobia, and clinically meaningful improvement in obsessive-compulsive disorder symptoms. In reproductive endocrinology, Unfer and colleagues at the Unfer Institute in Rome established that myo-inositol supplementation (2-4g/day) improves ovulation, reduces hyperandrogenism, and improves pregnancy rates in women with PCOS — with meta-analyses consolidating these findings across 20+ trials (Unfer 2017 Int J Endocrinol PMID: 29081797, Laganà et al. 2018). In obstetrics, D'Anna and colleagues at the University of Messina demonstrated that myo-inositol 4g/day taken from early pregnancy reduces the incidence of gestational diabetes mellitus (GDM) in high-risk pregnancies by approximately 50% (D'Anna 2013, 2015 PMIDs: 23345600, 25829487) — findings with substantial public-health implications that have been incorporated into some international guidelines for GDM prevention. The 40:1 myo-inositol to D-chiro-inositol ratio has emerged as the dominant combination convention for PCOS and fertility applications, based on research by Nordio, Unfer, and colleagues showing that this ratio approximates the physiological ratio in follicular fluid and produces superior outcomes compared to either isomer alone or other ratios. This 40:1 ratio (typically 2000mg myo-I + 50mg DCI) is embodied in commercial products like Inofolic Plus and is the default recommendation for most reproductive applications. For non-reproductive applications (anxiety, OCD, depression, insulin resistance), myo-inositol alone at higher doses is more commonly used. Mechanistic understanding of inositol's clinical effects centers on its role in insulin signaling and phosphoinositide second messenger systems. Insulin binding to its receptor triggers a signaling cascade that includes generation of inositol phosphoglycans (IPGs) from glycosylphosphatidylinositol (GPI) lipids — myo-inositol-containing IPGs (MI-IPG) activate enzymes promoting glucose uptake and utilization, while D-chiro-inositol-containing IPGs (DCI-IPG) activate enzymes promoting glycogen synthesis. Insulin-resistant states — including PCOS (where ovarian insulin resistance is a core feature), obesity-related metabolic syndrome, and type 2 diabetes precursors — involve dysregulation of these IPG systems. Supplemental inositol appears to partially restore signaling efficiency, producing improvements in insulin sensitivity, reduced compensatory hyperinsulinemia, reduced ovarian androgen production, improved ovulation, and (in pregnancy) reduced gestational diabetes risk. In psychiatric applications, the mechanism is less clear but likely involves the phosphatidylinositol-linked neurotransmitter signaling systems (serotonin 5-HT2, muscarinic cholinergic, adrenergic-α1 receptors all signal partly through PI-PLC/IP3), with inositol depletion potentially implicated in lithium's mood-stabilizing mechanism (the "inositol depletion hypothesis" of Berridge). Regulatory status is complex: Inositol is classified as a dietary supplement in the United States and most countries, available without prescription. It is generally-recognized-as-safe (GRAS) at typical doses. In some European countries, pharmaceutical-grade inositol preparations are marketed for PCOS and gestational diabetes prevention with more formal regulatory oversight. It was historically designated "Vitamin B8" but this classification has been largely abandoned since humans synthesize sufficient inositol endogenously. The safety profile across extensive clinical use (including high-dose 12-18g/day psychiatric use and millions of pregnancies exposed to 4g/day for GDM prevention) is excellent. See also Metformin, Berberine, DHEA, Ashwagandha, Magnesium, N-acetylcysteine, Vitamin D, and Omega-3 for adjacent insulin-sensitizing, anti-inflammatory, and hormonal-support compounds commonly used in PCOS and metabolic tuning. This is educational content and not medical advice — while inositol is very safe, clinical applications (particularly in pregnancy, with psychotropic medications, or with diabetes medications) warrant physician-level guidance.

Also known as: Dream Spray Blend

Proprietary nasal spray blend designed to support deep sleep and recovery.